Neurobiological Technologies, Inc.
NTIIOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$2702
P/E Ratio—
52W High$0.0001
52W Low$0.000001
Neurobiological Technologies, Inc. (NTII) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NTII · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2009-06 | 2008-06 | 2007-06 | 2006-06 | 2005-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $26.35M | $14.76M | $17.67M | $12.34M | $3.10M |
| Cost of Revenue | $0.13M | $0.20M | $0.23M | $0.19M | $0.07M |
| Gross Profit | $26.22M | $14.55M | $17.44M | $12.14M | $3.03M |
| Gross Margin %(computed) | 99.50% | 98.61% | 98.70% | 98.43% | 97.67% |
| Operating Expenses | |||||
| R&D Expenses | $17.58M | $24.58M | $26.74M | $22.81M | $10.75M |
| G&A Expenses | $5.08M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $22.86M | $31.25M | $33.04M | $40.28M | $28.33M |
| Operating Income | $3.49M | ($16.70M) | ($15.60M) | ($27.94M) | ($25.23M) |
| Operating Margin %(computed) | 13.25% | -113.12% | -88.28% | -226.43% | -813.90% |
| Interest Income | $0.75M | $1.25M | $0.00M | $0.00M | $0.25M |
| Interest Expense | $0.00M | $2.48M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $3.12M | ($16.32M) | ($14.13M) | ($27.54M) | ($25.23M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.30M | $0.00M |
| Net Income | $3.12M | ($16.32M) | ($14.13M) | ($27.84M) | ($24.98M) |
| Net Margin %(computed) | 11.85% | -110.58% | -79.94% | -225.62% | -805.86% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.12 | $-0.84 | $-3.26 | $-6.86 | $-6.58 |
| Wtd Avg Shares | 26.93M | 19.44M | 4.34M | 4.07M | 3.79M |
| EBITDA | $3.25M | ($16.49M) | ($15.37M) | ($16.24M) | ($12.48M) |
| EBITDA Margin %(computed) | 12.35% | -111.73% | -86.97% | -131.64% | -402.55% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Neurobiological Technologies, Inc. data
About Neurobiological Technologies, Inc. (NTII) Income Statement
Neurobiological Technologies, Inc. (NTII) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2009, NTII reported revenue of $0.03B, gross profit of $0.03B (gross margin 99.50%), and net income of $0.00B — a net profit margin of 11.85%.
Frequently asked questions
NTII · 4 questionsNeurobiological Technologies, Inc. (NTII) reported revenue of $0.03B for 2009, up 78.5% year-over-year.
NTII revenueNTII salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08